| Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012] | Technology appraisal guidance | TBC |
| Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259] | Technology appraisal guidance | TBC |
| Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398] | Technology appraisal guidance | TBC |
| Colon cancer (adjuvant) - irinotecan [ID379] | Technology appraisal guidance | TBC |
| Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826] | Technology appraisal guidance | TBC |
| Dapagliflozin for treating chronic kidney disease [ID6411] | Technology appraisal guidance | |
| Daprodustat for treating anaemia in people with chronic kidney disease [ID3987] | Technology appraisal guidance | TBC |
| Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated
multiple myeloma when a stem cell transplant is unsuitable [ID3843] | Technology appraisal guidance | |
| Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable ID6249 | Technology appraisal guidance | |
| Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer ID6452 | Technology appraisal guidance | |
| Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297 | Technology appraisal guidance | TBC |
| Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297 | Technology appraisal guidance | |
| Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348] | Technology appraisal guidance | TBC |
| Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241] | Technology appraisal guidance | TBC |
| DCVax-L for treating glioblastoma [ID836] | Technology appraisal guidance | TBC |
| Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419] | Technology appraisal guidance | TBC |
| Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID3897 | Technology appraisal guidance | TBC |
| Delgocitinib for treating moderate to severe chronic hand eczema ID6408 | Technology appraisal guidance | |
| Depemokimab for treating severe eosinophilic asthma in people 12 years and over ID6447 | Technology appraisal guidance | TBC |
| Dexmedetomidine for treating agitation associated with bipolar disorder in people 18 to 75 years [TS ID 10725] | Technology appraisal guidance | TBC |
| Dexmedetomidine for treating agitation associated with schizophrenia TS ID 10726 | Technology appraisal guidance | TBC |
| Diabetic retinopathy - ruboxistaurin [ID382] | Technology appraisal guidance | TBC |
| Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222] | Technology appraisal guidance | |
| Donidalorsen for preventing hereditary angioedema attacks in people 12 years and over [ID6457] | Technology appraisal guidance | TBC |
| Dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency ID6415 | Technology appraisal guidance | |
| Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314] | Technology appraisal guidance | TBC |
| Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055] | Technology appraisal guidance | TBC |
| Dupilumab for treating moderate to severe chronic obstructive pulmonary disease ID6235 | Technology appraisal guidance | TBC |
| Dupilumab for treating severe chronic rhinosinusitis with nasal polyposis (Review of TA648) [ID6480] | Technology appraisal guidance | |
| Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263] | Technology appraisal guidance | TBC |
| Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5073] | Technology appraisal guidance | |
| Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer
[ID6490] | Technology appraisal guidance | TBC |
| Durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating muscle-invasive bladder cancer [ID6168] | Technology appraisal guidance | |
| Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317 | Technology appraisal guidance | |
| Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725] | Technology appraisal guidance | |
| Efgartigimod for treating generalised myasthenia gravis [ID4003] | Technology appraisal guidance | TBC |
| Efgartigimod with recombinant human hyaluronidase PH20 for treating chronic inflammatory demyelinating polyneuropathy ID6409 | Technology appraisal guidance | TBC |
| Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060] | Technology appraisal guidance | TBC |
| Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240] | Technology appraisal guidance | TBC |
| Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177] | Technology appraisal guidance | |
| Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845] | Technology appraisal guidance | |
| Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable [ID6332] | Technology appraisal guidance | |
| Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338] | Technology appraisal guidance | TBC |
| ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623] | Technology appraisal guidance | TBC |
| Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920 | Technology appraisal guidance | TBC |
| Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393] | Technology appraisal guidance | TBC |
| Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071] | Technology appraisal guidance | TBC |
| Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032] | Technology appraisal guidance | TBC |
| Finerenone for treating heart failure with preserved or mildly reduced ejection fraction ID6514 | Technology appraisal guidance | TBC |
| Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133] | Technology appraisal guidance | TBC |